SCHEMBL4026436

SCHEMBL4026436

COCCN1C[C@H](C(=O)c2cccc(OC)c2)[C@H](c2cccc(F)c2C)[C@@H](C(=O)c2ccccc2F)C1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM2B Q8NHM5 5/20 0.42
KMT2A Q03164 2/20 0.40
HTT P42858 1/20 0.40
DRD2 P14416 1/20 0.39
DRD3 P35462 1/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
MCHR1 Q99705 1/20 0.38
MC4R P32245 1/20 0.38
NPSR1 Q6W5P4 2/20 0.38
THRB P10828 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
KAT6A Q92794 1/20 0.38
ALDH1A1 P00352 2/20 0.37
LMNA P02545 1/20 0.37
MEN1 O00255 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4020026 0.94 KDM2B (0.42) KDM2BKMT2AHTTDRD2DRD3
SCHEMBL4749342 0.92 KDM2B (0.40) KDM2BKMT2AHTTDRD2DRD3
SCHEMBL4021139 0.90 KDM2B (0.43) KDM2BKMT2AHTTDRD2DRD3
SCHEMBL4023629 0.90 KDM2B (0.39) KDM2BKMT2AHTTDRD2RAB9A
SCHEMBL13721312 0.90 KDM2B (0.39) KDM2BKMT2AHTTDRD2RAB9A
SCHEMBL4022127 0.90 KDM2B (0.39) KDM2BKMT2AHTTDRD2RAB9A
SCHEMBL4023627 0.90 KDM2B (0.39) KDM2BKMT2AHTTDRD2RAB9A
SCHEMBL4019477 0.88 DRD4 (0.41) KDM2BDRD2SMN1; SMN2MCHR1THRB
SCHEMBL4021684 0.88 KDM2B (0.38) KDM2BKMT2AHTTDRD2RAB9A
SCHEMBL4022391 0.87 KDM2B (0.37) KDM2BKMT2AHTTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
EP-1962846-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-09-03 EP claimed
WO-2007059323-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-24 WO claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
EP-1962846-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-09-03 EP disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed
WO-2007059323-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 KDM2B 3090/4885KMT2A 2820/4885HTT 2084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.